Opendata, web and dolomites

SixthSense

Early diagnosis of cervical cancer through the validation of Human Papilloma Virus viral load and expression of oncogenic viral proteins E6/E7 as risk indicators

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "SixthSense" data sheet

The following table provides information about the project.

Coordinator
PATHOFINDER BV 

Organization address
address: RANDWYCKSINGEL 45
city: MAASTRICHT
postcode: 6229 EG
website: www.pathofinder.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-04-01   to  2015-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PATHOFINDER BV NL (MAASTRICHT) coordinator 50˙000.00

Map

 Project objective

Infection with certain Human Papilloma Virus (HPV) types has been demonstrated as the most important risk factor in the development of cervical dysplasia, found to be present in nearly 100% of women with cervical cancer. Currently implemented mass-screening approaches based on imaging, Pap testing and DNA testing display some relevant drawbacks in terms of specificity and sensitivity, and even when one is diagnosed with HPV, there is practically no way to determine whether this infection will regress (90% of the cases), or will turn into cancer, with obvious economic and societal consequences. Through the SixthSense Project, PathoFinder will validate a diagnostic algorithm for HPV screening able to detect the presence of oncogenic/high-risk types HPV DNA, and to measure their viral load and expression of oncogenic viral proteins E6/E7, which will be used as risk indicators for the development of cervical cancer, thus allowing to timely diagnose who will develop cancer, and initiate the treatment accordingly. The objective is to manufacture and worldwide distribute this new assay and the associated analytical device, leveraging the proprietary new generation multiplex and Real Time PCR technology for rapid detection and identification of human pathogens in clinical specimens. This result will allow women to accurately know their risk to develop cancer undergoing only one gynaecological sampling/visit for both first line and second line testing, avoiding unnecessary and excessive follow up procedures. At the same time National Healthcare Systems would reduce the costs of unnecessary follow up visits and of more invasive investigations, while gynaecologist would also be favoured in the management of patients with low grade dysplasia.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SIXTHSENSE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SIXTHSENSE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

FURTHER (2019)

Focused Ultrasound and RadioTHERapy for Noninvasive Palliative Pain Treatment in Patients with Bone Metastasis

Read More  

HEADSpAcE (2019)

Translational studies of HEAD and neck cancer in South America and Europe

Read More  

BETTER-B (2019)

BETTER TREATMENTS FOR BREATHLESSNESS IN PALLIATIVE AND END OF LIFE CARE

Read More